AbCellera Biologics Inc.
ABCL
$3.65
$0.082.24%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 10.10% | 2.34% | -8.07% | -14.28% | -11.24% |
| Total Depreciation and Amortization | -55.66% | -96.96% | -44.78% | 112.30% | 110.39% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 276.27% | 2,579.41% | 78.03% | -80.16% | -74.07% |
| Change in Net Operating Assets | -173.55% | 75.66% | 110.72% | 26.67% | -295.41% |
| Cash from Operations | -20.95% | 12.99% | 11.54% | -88.82% | -147.41% |
| Capital Expenditure | 45.44% | 37.10% | 26.41% | 24.63% | -1.88% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -34.68% | -30.10% | -40.54% | 269.16% | 238.60% |
| Cash from Investing | -27.72% | -21.29% | -65.42% | 339.09% | 154.91% |
| Total Debt Issued | 120.26% | 65.57% | 10.67% | 13.86% | 16.46% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -2,046.64% | -1,177.75% | -1,174.56% | -53.29% | 40.92% |
| Cash from Financing | 10.28% | 13.86% | -37.76% | 16.58% | 23.30% |
| Foreign Exchange rate Adjustments | 141.92% | -321.44% | 46.03% | -6,033.33% | -544.31% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -223.30% | 5.02% | -77.75% | 151.40% | 109.06% |